Fund+ Establishes ExeVir Bio with VIB and UCB to Accelerate Development of New Treatment Conferring Broad Protection Against Covid-19
Fund+ Establishes ExeVir Bio with VIB and UCB to Accelerate Development of New Treatment Conferring Broad Protection Against Covid-19 Leads Series A Financing of EUR23M to Advance Lead Novel Llama-derived Antibody into Clinical Trials ExeVir Bio’s Technology Platform has Potential to Generate Robust Antiviral Therapies Fund+ Partner Philippe Monteyne will join the Board Belgium, […]
Read Post
Fund+ Leads EUR38 Million Series B Financing in Indigo Diabetes NV
Fund+ Leads EUR38 Million Series B Financing in Indigo Diabetes NV o Fund+ strengthens portfolio with medical device company developing a novel ‘invisible’ sensor for diabetes o Jan Van den Bossche Partner at Fund+ will join the Board Belgium, 27 July 2020: Fund+, an investment firm focused on innovative European Life Sciences companies, today […]
Read Post
Aelin Therapeutics awarded €2.3 million VLAIO research grant
Aelin Therapeutics awarded €2.3 million VLAIO research grant Funding will enable accelerated development of unique Pept™-in-based cancer therapeutics Leuven, BELGIUM – 9 July 2020 – Aelin Therapeutics NV, an emerging biotechnology company focused on the discovery and development of breakthrough Pept-in™-based therapeutics with novel modes of action to treat cancer and serious infectious diseases, today announces […]
Read Post
eTheRNA raises EUR 34 million in Series B financing to accelerate multiple mRNA therapeutic development programs through toclinical proof of concept
eTheRNA raises EUR 34 million in Series B financing to accelerate multiple mRNA therapeutic development programs through toclinical proof of concept Advancing oncology and infectious diseases pipeline, including new SARS-CoV-2 program Proprietary mRNA TriMix technology provides unprecedented immune responses Ongoing clinical trials in metastatic melanoma and breast cancer Proprietary LNP platform for […]
Read Post
Fund+ Announces Investment in Ona Therapeutics EUR30 Million Series A financing
Fund+ Announces Investment in Ona Therapeutics EUR30 Million Series A financing o Fund+ building a strong and diversified oncology portfolio o Alexandra Tolia, Partner at Fund+ will join the Board Belgium, 16 June 2020: Fund+, an investment firm focused on innovative European Life Sciences companies, today announces that it has invested in a […]
Read Post
Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19 NEW YORK, June 15, 2020 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced dosing of the first patients in its […]
Read Post
Notable Board Changes
Notable Board Changes Fund+ Appoints Luc Debruyne and Gérard Lamarche to the Board of Directors Belgium, 15 June 2020: Fund+, an investment firm focused on innovative European Life Sciences companies, today announced changes to the Board following the AGM. Luc Debruyne and Gérard Lamarche have been appointed to the Board of Fund+. In accordance […]
Read Post
Confo Therapeutics Expands Board with Appointment of Rob Scott as Independent Director
Confo Therapeutics Expands Board with Appointment of Rob Scott as Independent Director Ghent, Belgium – June 10, 2020 – Confo Therapeutics today announced the addition of a new member to its Board of Directors with the appointment of Rob Scott, MD, as an Independent Director. Dr. Scott’s career spans 30 years of drug discovery […]
Read Post
Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock
Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock NEW YORK, June 10, 2020 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the pricing of its previously announced public offering for the offering of […]
Read Post
Novadip Biosciences to unveil its 3M3 Platform at BIO Digital 2020
Novadip Biosciences to unveil its 3M3 Platform at BIO Digital 2020 Unique 3M3 tissue regeneration technology platform generates multiple product candidates: autologous, off-the-shelf and miRNA/exosome Mont-Saint Guibert, Belgium, 4 June, 2020: Novadip Biosciences (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company leveraging its unique tissue regeneration technology platform to generate multiple product candidates, announces […]
Read Post
Confo Therapeutics Appoints Paolo Vicini as Chief Development Officer
Confo Therapeutics Appoints Paolo Vicini as Chief Development Officer –New management role underscores Company’s commitment to establishing and advancing its proprietary pipeline of GPCR modulating drug candidates– Ghent, Belgium – June 3, 2020 – Confo Therapeutics today announced the appointment of Paolo Vicini, PhD, MBA, in the newly-created position of Chief Development Officer (CDO) effective […]
Read Post
HORAMA appoints life sciences veteran Benedikt Timmerman as new Chairman
HORAMA appoints life sciences veteran Benedikt Timmerman as new Chairman Paris, France, May 18, 2020 ‐ HORAMA, a clinical stage gene therapy company in ophthalmology, today announced that seasoned life sciences executive Dr. Benedikt Timmerman is taking over as the firm’s new Chairman. Benedikt has over 25 years of experience building and leading businesses in […]
Read Post
Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients
Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients NEW YORK, May 13, 2020 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and […]
Read Post
Novadip Biosciences Reports Positive Interim Analysis of Phase I/II Bone Non-Union Study with NVD003
Novadip Biosciences Reports Positive Interim Analysis of Phase I/II Bone Non-Union Study with NVD003 – Bone healing demonstrated at six-months after treatment with favorable safety profile – NVD003 is an autologous cell-based osteogenic product Mont-Saint Guibert, Belgium, 13 May, 2020: Novadip Biosciences (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company leveraging its proprietary tissue regeneration […]
Read Post
HORAMA appoints industry veteran Ian Catchpole as Chief Scientific Officer
HORAMA appoints industry veteran Ian Catchpole as Chief Scientific Officer Paris, France, May 4, 2020 ‐ HORAMA, a clinical stage gene therapy company in ophthalmology, today announced the appointment of Dr. Ian Catchpole as its Chief Scientific Officer. Ian will draw on his 25‐ plus years of experience in drug discovery and development to oversee […]
Read Post
Immunic, Inc. Announces Pricing of $15 Million Financing
Immunic, Inc. Announces Pricing of $15 Million Financing NEW YORK, April 23, 2020 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that it has entered into securities purchase agreements with certain institutional investors, led by Altium […]
Read Post
Aelin Therapeutics appoints Alexander Scheer, Ph.D., as Chief Scientific Officer
Aelin Therapeutics appoints Alexander Scheer, Ph.D., as Chief Scientific Officer Dr. Scheer brings over 25 years of international life science experience in multiple disciplines, technologies and therapeutic areas Leuven, BELGIUM – 23 April 2020 – Aelin Therapeutics NV, an emerging biotechnology company focused on the discovery and development of breakthrough Pept-in™-based therapeutics with novel […]
Read Post
Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients
Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients – In Cellular Assays with SARS-CoV-2 Clinical Isolates, IMU-838 Shows Ability to Inhibit Viral Replication of SARS-CoV-2 – – Live Webcast will be Held at 8:00am […]
Read Post
iTeos Therapeutics Closes $125 Million Series B2 Financing
iTeos Therapeutics Closes $125 Million Series B2 Financing – Proceeds support advancing clinical development of next-generation cancer immunotherapies targeting A2A adenosine receptor and anti-TIGIT immune checkpoint – – Oversubscribed round co-led by new investors RA Capital Management and Boxer Capital – – New investors Janus Henderson Investors, RTW Investments and Invus also participated along with […]
Read Post
eTheRNA launches an international consortium and starts development of cross-strain protective CoV-2 mRNA vaccine for high risk populations
eTheRNA launches an international consortium and starts development of cross-strain protective CoV-2 mRNA vaccine for high risk populations Niel, Belgium: eTheRNA Immunotherapies nv (‘eTheRNA’ or ‘The Company’), a clinical-stage company developing vaccines and immunotherapies from its proprietary mRNA TriMix platform, today announced that a consortium has been formed with North American and European partners […]
Read Post
HORAMA Signs Exclusive License Agreement with Leiden University Medical Center Targeting CRB1 Gene Mutations to Treat Inherited Retinal Dystrophies
HORAMA Signs Exclusive License Agreement with Leiden University Medical Center Targeting CRB1 Gene Mutations to Treat Inherited Retinal Dystrophies Further expansion of HORAMA gene therapy portfolio to treat Inherited Retinal Dystrophies to lead to second clinical program by 2023 Paris (France) and Leiden (Netherlands), March 18, 2020 ‐ HORAMA SA, a French biotechnology company focusing […]
Read Post
Job opening at Fund+ / Internship
Job opening Internship Fund+ is seeking an Intern to support its team during a 3-6 month placement. We are looking for someone with passion for life sciences and startups and make the first step to develop a career in Venture Capital investments. Our purpose is to make long term investments in highly innovative, life science companies primarily active in […]
Read Post
Job opening at Fund+ / Senior Associate
Job opening Senior Associate Fund+ is seeking a Senior Associate who can contribute to the value creation of our investments. Our purpose is to make long term investments in highly innovative, life science companies primarily active in therapeutics, as well as companies developing diagnostics and medical devices, with strong long-term potential. The combination of our open-ended […]
Read Post
HORAMA strengthens its management team with the appointment of Rodolphe Clerval as Chief Business Officer (CBO)
HORAMA strengthens its management team with the appointment of Rodolphe Clerval as Chief Business Officer (CBO) Paris, France, March 11th, 2020 – HORAMA, a clinical stage gene therapy company in ophthalmology, today announced that Rodolphe Clerval has been appointed as Chief Business Officer (CBO). Rodolphe has a strong track record of executing strategic partnerships, business […]
Read Post
iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers
iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers – First patient enrolled in dose escalation portion of Phase 1/2 study of EOS-448, an antagonist anti-TIGIT antibody that enables antibody dependent cellular cytotoxicity (ADCC) – – ADCC-enabled TIGIT programs are progressing into pivotal trials –– – clinical data expected in […]
Read Post